Retro-SCTL Space Block vs Rhomboid Intercostal Block for Analgesia After Modified Radical Mastectomy
Breast Cancer · Modified Radical Mastectomy · Postoperative Pain
What this study involves
The registry does not currently label this study as recruiting. Ask about its status before planning a screening visit.
- Study type
- Interventional
- Phase
- Not applicable
- Age range
- 18 years - 70 years
- Sex eligible
- Female
- Healthy volunteers
- Not accepted
- Participants
- 88 Estimated
These are starting points, not an eligibility decision. The research team must review the full requirements.
About the research
Modified radical mastectomy causes significant acute postoperative pain. The rhomboid intercostal block (RIB) is an established posterior chest wall block for breast surgery. The retro superior costotransverse ligament space (retro-SCTLS) block is a newer paraspinal block that may spread toward the paravertebral space, giving broader dermatomal coverage of the breast and axilla. This randomized trial will compare the two blocks in 88 adult women having elective unilateral modified radical mastectomy at Mansoura University Oncology Center. Each block uses 20 mL of 0.25% bupivacaine, given before general anesthesia under light dexmedetomidine sedation. The primary outcome is total intravenous morphine consumption in the first 24 hours after surgery. Secondary outcomes include pain scores, time to first rescue analgesia, intraoperative fentanyl use, sensory block extent, nausea and vomiting, block-related adverse events, quality of recovery (QoR-15), patient satisfaction and persistent pain at 3 months.
Read the full description
Patients will be randomized 1:1 to retro-SCTLS block at T3-T4 or RIB at T5-T6, using a computer-generated sequence with variable block sizes and sequentially numbered opaque sealed envelopes. To maintain blinding, both regions will be scanned in all patients and identical dressings applied at both sites. Sensory block (cold testing, T1-T6 and axilla) will be assessed 30 minutes after injection by a blinded assessor. General anesthesia and postoperative multimodal analgesia are standardized: paracetamol 1 g IV every 6 h and ketorolac 30 mg IV every 12 h, with rescue morphine 2 mg IV for NRS ≥ 4. The primary analysis is intention-to-treat using the Mann-Whitney U test, with the Hodges-Lehmann median difference and 95% CI. Assuming a 2 mg difference and a conservative SD of 3.1 mg (two-sided α 0.05, 80% power), 39 patients per group are required; 44 per group (88 total) will be enrolled to allow for 10% dropout.
Who may be able to participate?
The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.
Inclusion Criteria:
- Female patients aged 18 to 70 years
- American Society of Anesthesiologists (ASA) physical status I or II
- Scheduled for elective unilateral modified radical mastectomy under general anesthesia
- Able to provide written informed consent and to cooperate with pre-induction sedation and sensory assessment
Exclusion Criteria:
- Known allergy to local anesthetics, dexmedetomidine, morphine, paracetamol, or non-steroidal anti-inflammatory drugs (NSAIDs)
- Coagulopathy or any other contraindication to regional anesthesia
- Infection at the block injection site
- Body mass index (BMI) greater than 40 kg/m²
- Significant cardiac, hepatic, or renal impairment (eGFR \< 60 mL/min/1.73 m²)
- Chronic opioid use (daily opioid intake for 4 weeks or more before surgery)
- Pre-existing chest wall neuropathy or chronic pain syndrome
- Psychiatric or cognitive disorder preventing pain reporting or cooperation with sedation
- Pregnancy
- Bilateral breast surgery or immediate breast reconstruction
- Previous ipsilateral breast or chest wall surgery (other than diagnostic biopsy)
- Thoracic spine deformity or previous thoracic spine surgery
- Contraindication to NSAIDs (e.g., active peptic ulcer disease)
- Hemodynamic instability or baseline bradycardia (heart rate \< 50 bpm) precluding dexmedetomidine use
Treatment, groups and participation
The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.
- Assignment
- Random assignment
- Masking
- Triple masked
Retro-SCTLS block
Ultrasound-guided retro superior costotransverse ligament space block at T3-T4 with 20 mL of 0.25% bupivacaine, before induction under dexmedetomidine sedation.
Procedure: Retro Superior Costotransverse Ligament Space Block
Rhomboid intercostal block
Ultrasound-guided RIB at T5-T6 with 20 mL of 0.25% bupivacaine, before induction under dexmedetomidine sedation.
Procedure: Rhomboid Intercostal Block
Retro Superior Costotransverse Ligament Space Block PROCEDURE
Single-injection block at T3-T4 under ultrasound guidance, with 20 mL of 0.25% bupivacaine injected into the space posterior to the superior costotransverse ligament. It is performed before general anesthesia under standardized dexmedetomidine sedation (0.5 mcg/kg load, then 0.3 mcg/kg/h).
Rhomboid Intercostal Block PROCEDURE
Single-injection block at T5-T6 under ultrasound guidance, with 20 mL of 0.25% bupivacaine injected into the fascial plane between the rhomboid major and intercostal muscles, medial to the scapula. It is performed before general anesthesia under the same standardized dexmedetomidine sedation (0.5 mcg/kg load, then 0.3 mcg/kg/h).
What researchers are measuring
Outcome measures describe what is being studied. They are not proof that a treatment works.
Primary measures
Cumulative 24-hour intravenous morphine consumption
Time frame: From arrival in the post-anesthesia care unit (PACU) to 24 hours postoperatively
Total rescue IV morphine (mg) given in the first 24 hours after surgery. Rescue morphine 2 mg IV is given when NRS at rest is ≥ 4 or on patient request, repeated every 10 minutes until NRS is \< 4.
Secondary measures
Postoperative pain scores at rest and on movement
Time frame: 1, 2, 4, 6, 12 and 24 hours after PACU arrival
Pain intensity on the Numerical Rating Scale (0 = no pain, 10 = worst imaginable pain), at rest and during ipsilateral shoulder abduction to 90°. If abduction isn't tolerated, three deep breaths are used instead.
Time to first rescue analgesia
Time frame: From PACU arrival to the first rescue morphine dose, assessed up to 24 hours postoperatively
Time (minutes) from PACU arrival to the first rescue morphine dose. Patients who need no rescue are censored at 24 hours.
Total intraoperative fentanyl consumption
Time frame: During surgery: from induction of anesthesia to end of surgery (approximately 2-3 hours)
Total fentanyl (mcg) given during surgery, including the induction dose and rescue doses (0.5 mcg/kg). Rescue is triggered when MAP or HR rises \> 20% above the pre-incision baseline for ≥ 2 minutes.
Extent of sensory block
Time frame: 30 minutes after block injection
Number of dermatomes (T1-T6 and axilla) with reduced or absent cold sensation (ethyl chloride) on the operative side compared with the contralateral side. Block success is defined as ≥ 3 contiguous dermatomes.
Incidence of postoperative nausea and vomiting (PONV)
Time frame: Assessed at 1, 2, 4, 6, 12, and 24 hours after PACU arrival (cumulative incidence up to 24 hours)
Number of patients with any episode of nausea, retching or vomiting.
Rescue antiemetic requirement
Time frame: Assessed at 1, 2, 4, 6, 12, and 24 hours after PACU arrival (cumulative requirement up to 24 hours)
Number of patients needing rescue metoclopramide 10 mg IV.
Block performance time
Time frame: Periprocedural: during block performance, before induction of anesthesia
Time (seconds) from first placement of the ultrasound probe on the skin to needle withdrawal.
Number of needle passes
Time frame: Periprocedural: during block performance, before induction of anesthesia
Number of needle redirections needed to reach the target plane (maximum 3).
Incidence of block-related adverse events
Time frame: From block performance up to 24 hours postoperatively
Number of patients with any of the following:
hypotension (MAP \< 65 mmHg or \> 20% decrease from baseline) bradycardia (HR \< 50 bpm) vascular puncture, hematoma or puncture-site infection pneumothorax (confirmed by lung ultrasound or chest X-ray) contralateral sensory block suggesting epidural spread local anesthetic systemic toxicity
Sedation score
Time frame: 1, 2, 4, 6, 12 and 24 hours after PACU arrival
Ramsay Sedation Scale (1 = anxious/agitated to 6 = no response).
Quality of recovery (QoR-15)
Time frame: Baseline (preoperatively, on the day of surgery) and 24 hours postoperatively
Quality of Recovery-15 questionnaire score (range 0-150; higher scores mean better recovery).
Patient satisfaction with postoperative analgesia
Time frame: 24 hours postoperatively
5-point Likert scale (1 = very dissatisfied, 5 = very satisfied).
Persistent postsurgical pain
Time frame: 3 months postoperatively
Incidence of pain at or near the surgical site present on ≥ 4 of the 7 days before assessment, by structured telephone interview. Intensity is rated on the NRS (0-10), and neuropathic features are screened with the DN4 interview questionnaire (DN4i, score 0-7; ≥ 3 suggests neuropathic pain).
Review the complete result tables and limitations in the official record.
Open official results ↗Research locations (1)
The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.
1 locations
Oncology Center Mansoura University (OCMU)Al Mansurah, Dakahlia Governorate, EgyptStatus unknown
Study team and timeline
- Lead sponsor
- Mansoura University
- Study start
- Nov 7, 2026 Estimated
- Primary completion
- Apr 20, 2027 Estimated
- Study completion
- Apr 30, 2027 Estimated
- First posted
- Nov 10, 2026 Actual
- Last updated
- Nov 10, 2026 Actual
Official study contacts
Official study title
Ultrasound-Guided Retro Superior Costotransverse Ligament Space Block Versus Rhomboid Intercostal Block for Postoperative Analgesia After Modified Radical Mastectomy: A Randomized, Blinded Superiority Trial
Ask Wellness Clinical Research
Your message goes to WCR, including when this study is run by another organization. WCR may offer general guidance but may not operate this trial, have access to its team or be able to enroll you.
Source: ClinicalTrials.gov API v2. Information is submitted by sponsors and investigators. NLM does not approve the safety or science of all listed studies. Registry disclaimer.
Retrieved: Nov 12, 2026 · Last registry update: Nov 10, 2026
